ArticleCurrent microbiology2025
Antifungal Activity and Mechanism of the Novel Antimicrobial Peptide Jelleine-Ic Against Candida albicans.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Candida albicans, an opportunistic fungus, is the most common cause of invasive candidiasis globally. Drug resistance and limited number of antifungal compounds highlight the necessity of new antifungal drugs to treat C. albicans infections. Antimicrobial peptides (AMPs) exhibit potential as antifungal agents. The novel AMP Jelleine-Ic designed by our group demonstrated superior antibacterial activity than its parent peptide Jelleine-I. This work investigated the antifungal activity, antibiofilm activity and mechanism of action of Jelleine-Ic against C. albicans. Jelleine-Ic showed stronger antifungal activity against C. albicans than Jelleine-I. It effectively inhibited biofilm formation and destructed the preformed biofilm of C. albicans. Notably, it exhibited synergistic effect when combined with Amphotericin B. At concentrations below 125 μg/mL, it was not hemolytic on rabbit red blood cells. Jelleine-Ic compromised cell wall integrity, increased the permeability of C. albicans cell membrane. Furthermore, upon entering the cell, Jelleine-Ic bound with DNA, altered the expression of genes involved in DNA replication and repair, and induced the production of intracellular reactive-oxygen species. Jelleine-Ic increased the survival of Galleria mellonella infected with C. albicans. Collectively, Jelleine-Ic effectively controlled C. albicans, and could be a potential replacement for antibiotics and other chemical fungicides in the treatment of fungal infections.
Indexed as
Identifiers
41085739What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.